UoB

Clinical Research Fellow

Department of Immunology and Immunotherapy - 108088 - Clinical

Closes 25 Oct 2026

Research

Science

Pay TBC

Year groups

Not specified

Deadline

25 Oct 2026

Field

Science

Sector

Research & Academia

Year groups

PhD / Postgraduate Research

Overview

The University of Birmingham has recently been awarded a £5M research grant to conduct a randomised placebo-controlled trial of oral vancomycin, as a treatment for primary sclerosing cholangitis (the VITALITY study).
Primary sclerosing cholangitis (PSC) is an autoimmune liver condition that most often occurs in association with inflammatory bowel disease (IBD).
Although rare (prevalence ~7 per 100,000), PSC represents a a major unmet need, with no licensed medical therapy proven to slow disease progression.
Consequently, PSC is a lead indication for liver transplantation.
Moreover, the disease recurs in approximately 30% of individuals post-transplant.
Adoptive faecal transfer studies have also shown that stool from people living with PSC is able to induce liver disease in germ-free mice.

What you'll do

This job role will be full time (100% FTE) for three years The post-holder will be expected to register for a higher degree and will be supported to apply for further development and additional funding if desired.
The CRF will lead on delivery of this trial, driving trial setup and participant recruitment in collaboration with CRCTU and University Hospitals Birmingham.

Eligibility

Funding structure

About the employer

Dates can shift each year. Always confirm the live deadline on the provider's own page before you apply.